On March 17, 2026 LabGenius Therapeutics ("LabGenius"), a drug discovery company combining artificial intelligence (AI), high-throughput experimentation and machine-learning to discover next-generation therapeutic antibodies, reported that a scientific poster will be presented at the AACR (Free AACR Whitepaper) Annual Meeting 2026, being held April 17–22, 2026, at the San Diego Convention Center, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will debut preclinical data for LGTX-101, the company’s selectivity-enhanced Nectin-4 x CD3 T-cell engager (TCE), demonstrating:
A preliminary pharmacokinetic profile that supports the potential for a Q2W–Q4W clinical dosing regimen
Robust T-cell activation in primary bladder cancer co-culture models at concentrations below 5 pM
No evidence of T-cell activation when peripheral blood mononuclear cells (PBMCs) are cultured with human primary keratinocytes, which are known to endogenously express Nectin-4
Robust and reproducible regression of established tumours in vivo in a humanised BT-474 xenograft mouse model with >90% tumour growth inhibition observed at dose levels as low as 0.1 mg/kg
Poster Presentation Details
Title A Novel Machine-Learning Derived Nectin-4 x CD3 Bispecific T-Cell Engager,
LGTX-101, Demonstrates High Degrees of Tumour Selectivity and Potently Induces Tumour Regression in vivo
Date and time Monday, April 20, 2026, 09:00–12:00 (PDT)
Poster details Number 1626 | Section 10 | Board 18
Location San Diego Convention Center, California
LGTX-101 Overview
LabGenius has developed LGTX-101, a selectivity-enhanced Nectin-4 x CD3 T-cell engager (TCE). The company’s lead optimisation platform, EVA,was used to discover and optimise a TCE for improved killing selectivity, potency, efficacy, and manufacturability. The biological mechanism underlying this enhanced selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, the optimised LGTX-101 can distinguish between healthy and diseased cells based on differential tumour-associated antigen expression.
(Press release, LabGenius Therapeutics, MAR 17, 2026, View Source [SID1234663617])